Previously treated cases tested for RR-/MDR-TB (%) in Chile
Chile: Previously treated cases tested for RR-/MDR-TB was 99.0% in 2024. ▬ Flat
Latest (2024)
99.0%
Change on year
up 23.8%
World rank
56th
of 180 countries
All-time high
100.0%
in 2007
All-time low
62.0%
in 2015
Years of data
20
2005–2024
Previously treated cases tested for RR-/MDR-TB in Chile, 2005–2024
Source: World Health Organization, Global Health Observatory.
Analysis
In 2024, previously treated cases tested for rr-/mdr-tb in Chile stood at 99.0%.
The figure is up 23.8% on the previous year and up 41.4% over ten years.
Over the whole period, previously treated cases tested for rr-/mdr-tb in Chile peaked at 100.0% in 2007 and was at its lowest, 62.0%, in 2015.
Chile ranks 56th of 180 countries on this measure, in the middle of the range.
Previously treated cases tested for RR-/MDR-TB in Chile, year by year
| Year | Value | Change |
|---|---|---|
| 2005 | 72.0% | — |
| 2006 | 65.0% | -9.7% |
| 2007 | 100.0% | +53.8% |
| 2008 | 91.0% | -9.0% |
| 2009 | 72.0% | -20.9% |
| 2010 | 100.0% | +38.9% |
| 2011 | 100.0% | +0.0% |
| 2012 | 74.0% | -26.0% |
| 2013 | 75.0% | +1.4% |
| 2014 | 70.0% | -6.7% |
| 2015 | 62.0% | -11.4% |
| 2016 | 64.0% | +3.2% |
| 2017 | 67.0% | +4.7% |
| 2018 | 74.0% | +10.4% |
| 2019 | 91.0% | +23.0% |
| 2020 | 82.0% | -9.9% |
| 2021 | 90.0% | +9.8% |
| 2022 | 77.0% | -14.4% |
| 2023 | 80.0% | +3.9% |
| 2024 | 99.0% | +23.8% |
Chile compared with similar countries
- Chile's 99.0% is above the median for high income countries, which is 83.0%, 1.2× the median. (57 countries reporting)
- Chile's 99.0% is above the median for Latin America & Caribbean, which is 85.0%, 1.2× the median. (29 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 80.0% | 65.0% | 100.0% | 5 |
| 2010s | 77.7% | 62.0% | 100.0% | 10 |
| 2020s | 85.6% | 77.0% | 99.0% | 5 |
Countries ranked near Chile
- 56 Burkina Faso 99.0% compare
- 58 Somalia 98.0% compare
- 58 Russia 98.0% compare
- 58 Saudi Arabia 98.0% compare
More health data for Chile
- Un projection of annual infant deaths, annual growth rate -1.71 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.4062 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,755 deaths per 1,000 people (2090)
- Number of infants who die before age 1 115 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -3.22 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0224 units per person (2025)
- Population ages 00-04, male, annual growth rate -3.16 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is previously treated cases tested for rr-/mdr-tb in Chile?
- Previously treated cases tested for rr-/mdr-tb in Chile was 99.0% in 2024, according to World Health Organization, Global Health Observatory.
- What is the highest previously treated cases tested for rr-/mdr-tb recorded in Chile?
- The highest recorded value was 100.0% in 2007.
- What is the lowest previously treated cases tested for rr-/mdr-tb recorded in Chile?
- The lowest recorded value was 62.0% in 2015.
- How does Chile rank for previously treated cases tested for rr-/mdr-tb?
- Chile ranks 56th out of 180 countries with data for 2024.
- Is previously treated cases tested for rr-/mdr-tb rising or falling in Chile?
- Over the last ten years it is up 41.4%. The long-run trend across the full record is flat.
- Where does this Chile data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Previously treated cases tested for RR-/MDR-TB (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 20 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).